357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| id |
doaj-0095415875fa461a8b86d9a4ab31a7f7 |
|---|---|
| record_format |
Article |
| spelling |
doaj-0095415875fa461a8b86d9a4ab31a7f72020-12-11T10:01:36ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0357357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myelomaCheryl Li0Lei Shen1Sabrina Collins2Adarsh Joshi3Subhasree Das4Kaveri Suryanarayan5Dean Bottino6Michael Curley7Dannie Wang8Michael Abadier9Ryan Larson10Xavier Parot11Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Cheryl Li Lei Shen Sabrina Collins Adarsh Joshi Subhasree Das Kaveri Suryanarayan Dean Bottino Michael Curley Dannie Wang Michael Abadier Ryan Larson Xavier Parot |
| spellingShingle |
Cheryl Li Lei Shen Sabrina Collins Adarsh Joshi Subhasree Das Kaveri Suryanarayan Dean Bottino Michael Curley Dannie Wang Michael Abadier Ryan Larson Xavier Parot 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma Journal for ImmunoTherapy of Cancer |
| author_facet |
Cheryl Li Lei Shen Sabrina Collins Adarsh Joshi Subhasree Das Kaveri Suryanarayan Dean Bottino Michael Curley Dannie Wang Michael Abadier Ryan Larson Xavier Parot |
| author_sort |
Cheryl Li |
| title |
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma |
| title_short |
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma |
| title_full |
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma |
| title_fullStr |
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma |
| title_full_unstemmed |
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma |
| title_sort |
357 tak-573, an anti-cd38–attenuated interferon alpha (ifnα) fusion protein (attenukine™), has demonstrated ifnα receptor (ifnar) pathway modulation in patients with relapsed/refractory multiple myeloma |
| publisher |
BMJ Publishing Group |
| series |
Journal for ImmunoTherapy of Cancer |
| issn |
2051-1426 |
| publishDate |
2020-11-01 |
| work_keys_str_mv |
AT cherylli 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT leishen 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT sabrinacollins 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT adarshjoshi 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT subhasreedas 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT kaverisuryanarayan 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT deanbottino 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT michaelcurley 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT danniewang 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT michaelabadier 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT ryanlarson 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma AT xavierparot 357tak573ananticd38attenuatedinterferonalphaifnafusionproteinattenukinehasdemonstratedifnareceptorifnarpathwaymodulationinpatientswithrelapsedrefractorymultiplemyeloma |
| _version_ |
1724386523218968576 |